The COVID-19 pandemic has had a significant impact on the management of adults with type 2 diabetes, including delays in the diagnosis of the condition, reductions in the rate of treatment optimisation and backlogs in diabetes reviews.1 When prioritising the care of patients, it is important to target vulnerable groups such as the elderly with type 2 diabetes for early intervention.1

Join us for a live webinar hosted by Dr Sarah Jarvis, General Practitioner, London and Clinical Director at and Dr David Strain, Senior Clinical Lecturer at the University of Exeter Medical School, and Honorary Consultant in Medicine. Together, they will discuss the ongoing learning points from the pandemic and consider in particular the priorities for the care of older people with type 2 diabetes moving forward and the potential role of the dipeptidyl peptidase-4 (DPP-4) inhibitor Trajenta (linagliptin).